Sarcopenia, or loss of muscle mass and strength, plays a major role in the disablement process in older adults and increases the risk of impaired physical performance, falls, physical disability, frailty, and death. Oxidative stress is a major mechanism implicated in the pathogenesis of sarcopenia; aging muscle shows increased oxidative damage to DNA, protein, and lipids. Carotenoids quench free radicals, reduce damage from reactive oxygen species, and appear to modulate redox-sensitive transcription factors such as NF-ÎșB that are involved in the upregulation of IL-6 and other proinflammatory cytokines. Recent epidemiological studies in community-dwelling older adults show that low serum/plasma carotenoids are independently associated with low skeletal muscle strength and the development of walking disability. These observations are consistent with a growing number of studies showing that a diet with high intake of fruits and vegetables is associated with a reduced risk of inflammation, hypertension, diabetes, cardiovascular disease, and mortality.
KeywordsAging; Carotene; Carotenoids; Cryptoxanthin; Inflammation; Lutein; Lycopene; Muscle; Sarcopenia; Zeaxanthin Sarcopenia, a condition characterized by loss of skeletal muscle mass and strength with aging, is considered a key factor in the process of disablement in older adults [1]. Sarcopenia is associated with decreased lower extremity performance [2], functional impairment [3], falls [4,5], physical disability [6][7][8], and frailty [9]. Low skeletal muscle strength is predictive of disability [10,11] and mortality [12,13]. About one-third of women and two-thirds of men sixty years and older in the US have sarcopenia, and the estimated direct health care cost attributable to sarcopenia in the US in 2000 alone was $18.5 billion [6].Humans lose about 20-40% of both skeletal muscle mass and strength from 20 to 80 years of age [14,15]. Age-related changes in skeletal muscle include a decrease in muscle crosssectional area, a loss of muscle fibers, and fiber atrophy, as well as a decrease in muscle strength. Currently, there is no formal, widely-accepted clinical definition for sarcopenia. Appendicular lean mass as determined by dual-energy X-ray absorptiometry (DEXA) 1 scanning [16] and skeletal muscle index as determined by bioelectrical impedance analysis (BIA) [17] have been used to define sarcopenia. However, the quality and composition of muscle fibers cannot be determined using DEXA or BIA, and alternatively, low skeletal muscle strength has been used as a measure of sarcopenia [18]. Low grip, hip, and knee strength are often used in epidemiological studies of aging to measure sarcopenia. In relation to the risk of *Corresponding